Results for tag: "Chemotherapy Induced Neutropenia"

In the context of healthcare services, the chemotherapy-induced neutropenia (CIN) market encompasses the range of medical treatments, products, and services used to prevent and manage neutropenia, a common side effect of chemotherapy where a patient's neutrophil count becomes abnormally low, increasing the risk of infection. The market includes pharmaceuticals such as colony-stimulating factors (CSFs), which stimulate the bone marrow to produce more white blood cells, antibiotics for the prevention and treatment of infections, and diagnostic services that monitor neutrophil counts and infection markers. Healthcare service providers such as hospitals, specialty clinics, and oncology centers play a crucial role in administering these treatments and monitoring patient health outcomes. Research and development efforts in this market aim to deliver more efficacious and safer therapies, with a focus on personalized medicine approaches that tailor treatment to individual patient needs and genetic profiles. Companies operating within the CIN market span a variety of pharmaceutical manufacturers and biotechnology firms. Some notable players include Amgen, which produces Neupogen and Neulasta, drugs that are commonly used to treat neutropenia, and Pfizer, which offers a biosimilar to Neulasta called Nivestym. Other companies involved in the production of treatments for CIN include Teva Pharmaceutical Industries, Novartis, and Mylan, which offer generic and biosimilar versions of CSFs and supportive care medications essential for managing neutropenia in chemotherapy patients. Show Less Read more